The company launches the drug under the brand name 'Hepcvir-L' costing Rs 25,000 for a bottle of 28 tablets in India.
Cipla Soon to Launch Generic Hepatitis C Drug as Hepcvir
Cipla has signed a licensing agreement with Gilead to manufacture the drug Sofosbuvir and it will be made available as Hepcvir in India.
Cipla has signed a licensing agreement with Gilead to manufacture the drug Sofosbuvir and it will be made available as Hepcvir in India.
‘Hepatitis C viral infection affects about 12-18 million in India and 185 million people globally.’
The company's product is a generic version of the drug maker Gilead Sciences Inc's Harvoni tablets. Gilead had decided to licence the manufacturing right of the medicine to generic companies to make it accessible in low-income countries soon after its launch in the US. Hepcvir-L is the first once-a-day, fixed dose oral combination therapy that has been approved for chronic hepatitis C genotype 1 patients.
Managing Director and Global Chief Executive Officer Subhanu Saxena said, “The launch of Ledipasvir-Sofosbuvir is a further step to facilitate the optimal treatment for patients suffering from genotype 1 hepatitis C virus.”
Mylan Soon to Distribute Hepatitis C Drugs in India
Mylan, US drug maker soon to distribute two drugs in India to treat liver diseases. Mylan Pharmaceuticals Private Limited, has received exclusive rights to distribute the branded medicines Sovaldi for liver diseases and Havaroni for chronic hepatitis C.
Mylan, US drug maker soon to distribute two drugs in India to treat liver diseases. Mylan Pharmaceuticals Private Limited, has received exclusive rights to distribute the branded medicines Sovaldi for liver diseases and Havaroni for chronic hepatitis C.
Access to Hepatitis C Drugs to be Expanded in Developing World
Gilead Sciences, US biotechnology firm, announced Monday it has signed generic licensing deals with seven India-based companies to increase access to Hepatitis C treatment in the developing world.
Gilead Sciences, US biotechnology firm, announced Monday it has signed generic licensing deals with seven India-based companies to increase access to Hepatitis C treatment in the developing world.
Natco Pharma and Hetero Receives Indian Drug Regulatory Approval for Hepatitis-C Drug
The companies have decided to sell generic version of Daclatasvir tablets in the strengths of 30 mg and 60 mg to treat hepatitis C virus infection in India.
The companies have decided to sell generic version of Daclatasvir tablets in the strengths of 30 mg and 60 mg to treat hepatitis C virus infection in India.
